Pazopanib Confers a Progression-free Survival in a Patient with Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Lung

Ewing's sarcoma (ES)/primitive neuroectodermal tumors (PNETs) are highly malignant neoplasms that usually affect the bones and soft tissues in children and young adults. ES/PNET of the lung is very rare and is associated with a poor prognosis. We herein report a case of ES/PNET of the left lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Takigami, Ayako, Yamasawa, Hideaki, Kurosaki, Ayako, Sakamoto, Noritaka, Onuki, Tsugitoshi, Mato, Naoko, Tetsuka, Kenji, Endo, Shunsuke, Niki, Toshiro, Bando, Masashi, Hagiwara, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543224/
https://www.ncbi.nlm.nih.gov/pubmed/30626819
http://dx.doi.org/10.2169/internalmedicine.1549-18
Descripción
Sumario:Ewing's sarcoma (ES)/primitive neuroectodermal tumors (PNETs) are highly malignant neoplasms that usually affect the bones and soft tissues in children and young adults. ES/PNET of the lung is very rare and is associated with a poor prognosis. We herein report a case of ES/PNET of the left lung in a 45-year-old man. He was treated with neoadjuvant chemotherapy and pneumonectomy, but unfortunately his disease recurred 1.5 months after surgery. He was started on pazopanib, which resulted in a five-month progression-free survival. To our knowledge, this is the first demonstration of pazopanib efficacy in ES/PNET of the lung.

Ejemplares similares